Mitochondrial dysfunction in microglia: a novel perspective for pathogenesis of Alzheimer’s disease

被引:0
作者
Yun Li
Xiaohuan Xia
Yi Wang
Jialin C. Zheng
机构
[1] Tongji Hospital Affiliated to Tongji University School of Medicine,Center for Translational Neurodegeneration and Regenerative Therapy
[2] Shanghai Frontiers Science Center of Nanocatalytic Medicine,Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Tongji University)
[3] Ministry of Education,Translational Research Institute of Brain and Brain
[4] Shanghai Fourth People’s Hospital affiliated to Tongji University School of Medicine,Like Intelligence
[5] Shanghai Yangzhi Rehabilitation Hospital Affiliated to Tongji University School of Medicine,Translational Research Center
[6] Tongji University,Collaborative Innovation Center for Brain Science
来源
Journal of Neuroinflammation | / 19卷
关键词
Microglia; Alzheimer’s disease; Mitochondria; Metabolism; mtDNA;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly globally. Emerging evidence has demonstrated microglia-driven neuroinflammation as a key contributor to the onset and progression of AD, however, the mechanisms that mediate neuroinflammation remain largely unknown. Recent studies have suggested mitochondrial dysfunction including mitochondrial DNA (mtDNA) damage, metabolic defects, and quality control (QC) disorders precedes microglial activation and subsequent neuroinflammation. Therefore, an in-depth understanding of the relationship between mitochondrial dysfunction and microglial activation in AD is important to unveil the pathogenesis of AD and develop effective approaches for early AD diagnosis and treatment. In this review, we summarized current progress in the roles of mtDNA, mitochondrial metabolism, mitochondrial QC changes in microglial activation in AD, and provide comprehensive thoughts for targeting microglial mitochondria as potential therapeutic strategies of AD.
引用
收藏
相关论文
共 193 条
  • [1] Scheltens P(2021)Alzheimer's disease Lancet 397 1577-1590
  • [2] Cornutiu G(2015)The epidemiological scale of Alzheimer's disease J Clin Med Res 7 657-666
  • [3] Gaugler J(2022)2022 Alzheimer's disease facts and figures Alzheimers Dement 18 700-789
  • [4] James B(2007)Forecasting the global burden of Alzheimer's disease Alzheimers Dement 3 186-191
  • [5] Johnson T(2015)Neuroinflammation in Alzheimer's disease Lancet Neurol 14 388-405
  • [6] Reimer J(2019)Structure based design and molecular docking studies for phosphorylated tau inhibitors in Alzheimer's disease Cells 8 260-1193
  • [7] Solis M(2020)Synergy between amyloid-β and tau in Alzheimer's disease Nat Neurosci 23 1183-292
  • [8] Weuve J(2011)Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 280-696
  • [9] Buckley RF(2021)Distinct amyloid-β and tau-associated microglia profiles in Alzheimer's disease Acta Neuropathol 141 681-156
  • [10] Hohman TJ(2021)Glutaminase in microglia: a novel regulator of neuroinflammation Brain Behav Immun 92 139-1599